menu search

MASI / Masimo: Staying Neutral Following Unchanged Guidance And Recent Developments

Masimo: Staying Neutral Following Unchanged Guidance And Recent Developments
Positive earnings surprises for Masimo Corporation in FY 2023 are less likely, taking into account Masimo's unchanged full-year financial guidance. It will be tough for Masimo's shares to witness a meaningful re-rating, considering recent developments relating to legal cases against Apple Inc. and an activist investor's attempt to appoint new directors. I maintain a Hold rating for Masimo Corporation, as I don't see any favorable catalysts for the stock in the near term. Read More
Posted: Jun 5 2023, 13:03
Author Name: Seeking Alpha
Views: 111680

MASI News  

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

By Zacks Investment Research
October 16, 2023

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to be more_horizontal

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

By Zacks Investment Research
October 10, 2023

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery. more_horizontal

Masimo: Lots Of Questions

By Seeking Alpha
September 25, 2023

Masimo: Lots Of Questions

Masimo Corporation shares fell after announcing a "diworsification" move for Sound United, causing concerns about the company's core expertise. Despit more_horizontal

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

By Zacks Investment Research
September 1, 2023

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes. more_horizontal

Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients

By Zacks Investment Research
August 22, 2023

Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI more_horizontal

Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise

By Zacks Investment Research
August 9, 2023

Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise

Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances. more_horizontal

Masimo (MASI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
August 8, 2023

Masimo (MASI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare more_horizontal

Masimo Corporation (MASI) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Masimo Corporation (MASI) Q2 2023 Earnings Call Transcript

Masimo Corporation (NASDAQ:MASI ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Eli Kammerman - VP, Business Develop more_horizontal


Search within

Pages Search Results: